Shopping Cart

Your shopping cart is currently empty

Mefenamic acid

Name: Mefenamic acid
Brand: TargetMol
SKU: T0890
Price: 31 USD
Availability: InStock
Rating: 5 (10 reviews)

Copy Product Info

😃Good

Catalog No. T0890Cas No. 61-68-7

Alias CN-35355, CI 473

Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Mefenamic acid

Copy Product Info

😃Good

Purity: 99.32%

Catalog No. T0890Alias CN-35355, CI 473Cas No. 61-68-7

Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.

Pack Size	Price	USA Warehouse	Global Warehouse
200 mg	$31	In Stock	In Stock
500 mg	$48	In Stock	In Stock
1 g	$58	In Stock	In Stock
5 g	$86	-	In Stock
1 mL x 10 mM (in DMSO)	$53	In Stock	In Stock

Add to Cart

Add to Quotation

In Stock Estimated shipping dateUSA Warehouse[1-2 days] Global Warehouse[5-7 days]

All TargetMol products are for research purposes only and cannot be used for human consumption. We do not provide products or services to individuals. Please comply with the intended use and do not use TargetMol products for any other purpose.

Questions

Batch Information

Select Batch

Purity:99.32%

Appearance:Solid

Color:White

Resource Download

COA LCMS HNMR HPLC

Product Introduction

Mefenamic acid AI Summary

Mefenamic acid exhibits a broad spectrum of bioactivities across various assays and biological systems. It has a calculated partition coefficient (cLogP) of 5.287, suggesting high lipophilicity, and shows limited intrinsic water solubility at 0.04 ug/mL which may impact its bioavailability. The compound demonstrates significant analgesic and anti-inflammatory activities, inhibiting the phenylquinone writhing response in mice (ED50 = 45.9 mg/kg) and carrageenan-induced edema in rats (33.1% at 40 mg/kg and 39.0% at 100 mg/kg). However, it also exhibits gastrointestinal toxicity with a high ulcer index and an impact on liver enzyme activity, particularly an increase in SGOT levels. Mefenamic acid effectively inhibits multiple enzymes including COX-1 and COX-2 (IC50 values of 116.0 nM and 602.0 nM, respectively), malate dehydrogenase (MDH), and beta-lactamase. Notably, it shows antiviral activity against JC polyomavirus and SARS-CoV-2, as well as antifungal and antibacterial activity against various pathogens. It affects several biomarkers related to liver function, such as ALT and AST, indicating moderate liver toxicity. The compound also demonstrates potential in modulating various receptors and enzymes, with significant activities in inhibiting HDAC6, activating TREK1 channels, and showing binding affinity to beta cyclodextrin (log Ks = 2.49). Additionally, Mefenamic acid shows inhibitory effects on key mitochondrial functions, transport proteins such as OATP1B3 and BSEP, and demonstrates a low brain-to-plasma ratio, indicating limited central nervous system penetration. Further studies have highlighted its inhibitory activity on enzymes related to mycobacterium tuberculosis growth, suggesting potential as an antimicrobial agent. Lastly, the compound interacts with multiple receptors including DRD1, ESR1, SLC6A2, and exhibits both agonist and antagonist activities in different biological contexts. Overall, Mefenamic acid showcases a diverse pharmacological profile affecting multiple physiological pathways and demonstrating significant potential for therapeutic applications, albeit with associated risks of toxicity..

Note: Summary generated by AI. Data source: ChEMBL

Bioactivity

Description	Mefenamic acid (CN-35355) is a non-steroidal anti-inflammatory agent with analgesic, anti-inflammatory, and antipyretic properties. It is an inhibitor of cyclooxygenase.
Targets&IC50	COX-2 (human):3 μM, COX-1 (human):40 nM
Synonyms	CN-35355, CI 473

Chemical Properties

Molecular Weight	241.29
Formula	C₁₅H₁₅NO₂
Cas No.	61-68-7
Smiles	CC1=C(C)C(NC2=C(C=CC=C2)C(O)=O)=CC=C1
Relative Density.	1.203 g/cm3

Storage & Solubility Information

Storage

Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature.

Solubility Information

Ethanol: < 1 mg/mL (insoluble or slightly soluble)

DMSO: 100 mg/mL (414.44 mM), Sonication is recommended.

In Vivo Formulation

10% DMSO+40% PEG300+5% Tween 80+45% Saline: 20 mg/mL (82.89 mM), Suspension.

Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions.

Solution Preparation Table

DMSO

	1mg	5mg	10mg	50mg
1 mM	4.1444 mL	20.7220 mL	41.4439 mL	207.2195 mL
5 mM	0.8289 mL	4.1444 mL	8.2888 mL	41.4439 mL
10 mM	0.4144 mL	2.0722 mL	4.1444 mL	20.7220 mL
20 mM	0.2072 mL	1.0361 mL	2.0722 mL	10.3610 mL
50 mM	0.0829 mL	0.4144 mL	0.8289 mL	4.1444 mL
100 mM	0.0414 mL	0.2072 mL	0.4144 mL	2.0722 mL

Calculator

Molarity Calculator
Dilution Calculator
Reconstitution Calculator
Molecular Weight Calculator

In Vivo Formulation Calculator (Clear solution)

Please enter your animal experiment information in the following box and click Calculate to obtain the stock solution preparation method and in vivo formula preparation method:

For example, if the intended dosage is 10 mg/kg for animals weighing 20 g , with a dosing volume of 100 μL per animal, TargetMol | Animal experiments

and a total of 10 animals are to be administered, using a formulation of TargetMol | reagent

10% DMSO+ 40% PEG300+ 5% Tween 80+ 45% Saline/PBS/ddH₂O , the resulting working solution concentration would be 2 mg/mL.

Stock Solution Preparation:

Dissolve 2 mg of the compound in 100 μL DMSO TargetMol | reagent to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.

Preparation of the In Vivo Formulation:

1) Add 100 μL of the DMSO TargetMol | reagent stock solution to 400 μL PEG300 and mix thoroughly until the solution becomes clear.

2) Add 50 μL Tween 80 and mix well until fully clarified.

3) Add 450 μL Saline,PBS or ddH₂O TargetMol | reagent and mix thoroughly until a homogeneous solution is obtained.

This example is provided solely to demonstrate the use of the In Vivo Formulation Calculator and does not constitute a recommended formulation for any specific compound. Please select an appropriate dissolution and formulation strategy based on your experimental model and route of administration.

All co-solvents required for this protocol, includingDMSO, PEG300/PEG400, Tween 80, SBE-β-CD, and Corn oil, are available for purchase on the TargetMol website.

Dose Conversion

You can also refer to dose conversion for different animals. More Dose Conversion

Tech Support

Please see Inhibitor Handling Instructions for more frequently ask questions. Topics include: how to prepare stock solutions, how to store products, and cautions on cell-based assays & animal experiments, etc